Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071-22072 and CORE Trials.
Julia FurtnerMichael WellerMichael WeberThierry GorliaLouis Burt NaborsDavid A ReardonJoerg C TonnRoger StuppMatthias Preussernull nullPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
TMT identifies ambulatory patients with newly diagnosed glioblastoma at risk for progressive sarcopenia and adverse outcomes. Early intervention may prevent skeletal muscle loss and improve patient outcome.